- Home
- YALA vs RLMD Comparison
YALA vs RLMD Comparison
Compare YALA & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YALA | RLMD |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 801.7M | 661.9M |
| IPO Year | 2020 | 2012 |
Fundamental Metrics
Financial Performance| Metric | YALA | RLMD |
|---|---|---|
| Price | $5.46 | $6.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.40 |
| AVG Volume (30 Days) | 345.7K | ★ 2.3M |
| Earning Date | 05-18-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,070.00 |
| Revenue This Year | $16.40 | N/A |
| Revenue Next Year | $7.13 | N/A |
| P/E Ratio | $8.76 | ★ N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $5.01 | $0.55 |
| 52 Week High | $9.29 | $8.00 |
Technical Indicators
Market Signals| Indicator | YALA | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 46.28 | 42.80 |
| Support Level | $5.23 | $6.17 |
| Resistance Level | $7.27 | $7.34 |
| Average True Range (ATR) | 0.18 | 0.45 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 68.12 | 1.75 |
Price Performance
Historical ComparisonAbout YALA Yalla Group Limited each representing one
Yalla Group Ltd is a MENA-based online social networking and gaming company. It operates two flagship mobile applications, Yalla, a voice-centric group chat platform, and Yalla Ludo, a casual gaming application featuring online versions of board games popular in MENA, with in-game voice chat and localized majlis functions. The group has one operating segment, which is the social networking and entertainment platform.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.